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Summary 1 
Background: Asthma is a chronic airway inflammatory disease, however, the molecular 2 
mechanisms that underlie asthma exacerbation are only partially understood.  3 
Objective: To identify gene expression signatures that reflect the acute exacerbation of 4 
asthma, we examined the differential expression of genes during asthma exacerbation 5 
and stable condition by using microarray analysis.  6 
Methods: The subjects were mite-sensitive asthmatic children and non-asthmatic control 7 
children. The children were divided into 4 groups (AE: asthma exacerbation, n = 12; 8 
SA: stable asthma, n = 11; IC: infected control, n = 6; and NC: non-infected control, n = 9 
5). Total RNA was extracted from peripheral blood mononuclear cells and subjected to 10 
microarray analysis with Illumina Human Ref8 BeadChip arrays. Welch’s t-test was 11 
performed to identify genes whose expression was altered during asthma exacerbation. 12 
Quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) was 13 
performed on samples collected from 43 asthmatic children and 11 control children to 14 
verify the microarray results. 15 
Results: The expression of 137/16 genes was significantly up/down-regulated during 16 
asthma exacerbation assessed by microarray analysis. Of the genes, 62 were also 17 
differentially expressed during upper respiratory infection. Many of the asthma 18 
 2
exacerbation related genes were involved in defense responses and responses to external 1 
stimuli, but these associations disappeared after excluding the infection-related genes. 2 
Quantitative real-time RT-PCR confirmed that the genes related (S100A8 and GAS6) 3 
and unrelated to infections (CD200 and RBP7) were differentially expressed during 4 
asthma exacerbation (P < 0.01). 5 
Conclusions Previously unidentified immune responses during asthma exacerbation 6 
may provide further clarification of the molecular mechanisms underlying asthma. 7 
 8 
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Introduction 1 
Asthma is the most common chronic disorder in childhood, and asthma exacerbation is 2 
an important cause of childhood morbidity and hospitalization. The prevalence of 3 
childhood asthma in Japan is 5.1% among infants, 6.4% among children and 3.2% 4 
among adults, and 1.146 million patients received ongoing medical care for asthma in 5 
1996 [1]. Costs for treatment of asthma have great financial impact on health care 6 
worldwide. It was reported that the number of disability-adjusted life years lost due to 7 
asthma worldwide is similar to that for diabetes, liver cirrhosis or schizophrenia [2].  8 
Asthma is a chronic airway inflammatory disease caused by infiltration of 9 
lymphocytes, mast cells and eosinophils into the airways, and T-helper type 2 cytokines 10 
play crucial roles in orchestrating the inflammatory responses [3]. Factors that influence 11 
asthma exacerbation include infections, such as those by Rhinovirus, Chlamydia and 12 
Mycoplasma species, and exposure to sensitized allergens [4-6]. However, the 13 
molecular mechanisms that underlie asthma exacerbation are only partially understood. 14 
To understand the molecular basis of asthma exacerbation, it would be helpful to 15 
examine expression of genes during asthma exacerbation. The microarray technique 16 
permits simultaneous analysis of expression of many genes. Therefore, large-scale gene 17 
expression analysis by microarray may clarify the disease pathways for asthma.  18 
 4
Two types of tissues have been used for human microarray studies of asthma. 1 
One is airway epithelium cells from patients and healthy subjects. Laprise et al. [7] 2 
performed microarray studies with tissue obtained from bronchial biopsies of 4 3 
asthmatic patients before and after inhaled corticosteroid therapy and from those of 4 4 
healthy subjects. Seventy-nine genes were differentially expressed between asthmatic 5 
subjects and controls, including nitric oxide synthase 2A (NOS2A), glutathione 6 
peroxidase 3 (GPX3), arachidonate 15-lipoxygenase (ALOX15), cystatin C (CTSC) and 7 
chemokine (C-X3-C motif) receptor 1 (CX3CR1). Lilly et al. [8] reported that 8 
expression of 141 sequences was up-regulated and 8 sequences were down-regulated 9 
during segmental allergen challenge in 5 asthmatic subjects and identified 10 
asthma-associated sequences, including the interleukin (IL)-3, IL-4 and IL-5 receptor 11 
subunit genes. Nasal mucosal cells obtained from subjects with childhood asthma with 12 
stable and exacerbated conditions as well as nonasthmatic controls were also analyzed, 13 
and expression of a large number of immune-related genes was up-regulated in 14 
exacerbated asthmatics [9]. 15 
Hansel et al. [10] performed microarray analysis of CD4+ T cells from patients 16 
with asthma. They identified 37 up-regulated and 3 down-regulated genes. Katsunuma 17 
et al. [11] performed differential display with T lymphocytes from patients with stable 18 
 5
and exacerbated childhood asthma and found that the genes encoding annexin II, IL-4, 1 
IL-5, interferon (IFN)-gamma, IL-12 receptor-beta, and integrin alpha 6 were expressed 2 
at higher levels during asthma exacerbation. Peripheral blood mononuclear cells 3 
(PBMCs) are easier to obtain and handle than bronchial epithelial cells. Lymphocytes, 4 
monocytes and dendritic cells in PBMCs are recognized as the sources of the cytokines 5 
related to allergic responses. Therefore, examining changes in expression of genes in 6 
PBMCs from asthmatic patients may provide clues regarding the disease pathway.   7 
In the present study, we performed microarray analysis to identify changes in 8 
gene expression that reflect acute exacerbation of asthma and constructed a pathway of 9 
the molecular changes that occur during asthma exacerbation.  10 
 6
Materials and methods 1 
Subjects 2 
Asthmatic patients were mite-sensitive asthmatic children who visited the pediatric 3 
clinic of Tsukuba Medical Center Hospital Tsukuba, Japan. Each patient was questioned 4 
regarding allergic symptoms and underwent a physical examination performed by a 5 
participating pediatrician. Asthma was diagnosed in patients according to the criteria of 6 
the US National Institutes of Health [3]. Asthmatic patients had to satisfy the following 7 
2 criteria: (1) 2 or more episodes of wheezing and shortness of breath during the 8 
previous 12 months and (2) reversibility of the wheezing and dyspnea, either 9 
spontaneously or in response to bronchodilator treatment. Methacholine challenge 10 
testing was not done because of the young ages of the asthma patients; however, 11 
differential diagnosis of asthma in the affected children was made by participating 12 
pediatricians who had treated the children for more than 1 year, and they confirmed 13 
each diagnosis of asthma. Total and specific IgE titers for Dermatophagoides farinae 14 
were determined with the Pharmacia CAP System (Uppsala, Sweden). Children with 15 
asthma exacerbation who required hospitalization (asthma exacerbation (AE) group) 16 
and those with stable asthma without any exacerbation in at least the past 4 weeks 17 
(stable asthma (SA) group) were enrolled in the study. All of the patients in AE group 18 
 7
had episodes of progressive increasing coughing and wheezing. Responses to the initial 1 
bronchodilator treatment were not prompt or sustained for more than 3 h, and no 2 
improvement was observed more than 2 h after administration of intravenous steroids. 3 
All of them were treated with 1mg/kg, 4 times/day of methylprednisolone for 1-3 days 4 
(mean 2.3 ± 0.7 days) after hospitalization and with inhaled short acting beta-2 agonists 5 
as combination therapy until their symptoms disappeared. Symptom such as wheezing 6 
and dyspnea disappeared within a few days in all children, and maximum duration of 7 
hospitalization was 7 days (mean 3.9 ± 1.8 days). Severity of asthma exacerbation in 8 
these patients was moderate to severe according to the guidelines of the Global 9 
Initiative of Asthma (GINA, http://www.ginasthma.com).  Exclusion criteria were (1) 10 
Fever ( >37.5 °C), (2) C-reactive protein (CRP) > 1.0 mg/ml, and (3) systemic steroid 11 
use prior to hospitalization. Children in SA group were independent from ones in AE 12 
group.  13 
Control subjects without allergies or infections (non-infected control (NC) 14 
group) had to satisfy all of the following criteria: (1) no symptoms or history of allergic 15 
diseases, (2) no detectable dust mite-specific IgE antibody and (3) total serum IgE levels 16 
below the general population mean for their ages, (4) no symptoms of infection during 17 
past 4 weeks. Because asthma exacerbation is often associated with respiratory infection, 18 
 8
we recruited patients with respiratory tract infections and mild fever as infected controls 1 
(IC) group. Children were included in the IC group if they satisfied both the following 2 
criteria: (1) symptomatic respiratory infection (coughing and rhinorrhoea associated 3 
with mild fever (37.5-38 ºC), and (2) the absence of symptoms or history of any allergic 4 
diseases. A full verbal and written explanation of the study was provided, and written 5 
informed consent was obtained from the patient or his/her parents. This study was 6 
approved by the Ethics Committees of the University of Tsukuba and the Tsukuba 7 
Medical Center Hospital. The clinical characteristics of each group are shown in Table 8 
1. 9 
 10 
RNA extraction 11 
Five milliliters of peripheral blood was taken from each patient. PBMCs were purified 12 
with Ficoll-PaqueTM gradient (GE Healthcare, Piscataway, NJ). RNA was extracted 13 
from PBMCs with an RNeasy Mini Kit (Qiagen K.K., Tokyo, Japan) according to the 14 
manufacturer’s instructions.  15 
We used Illumina BeadArray with single-color array (Illumina, San Diego, CA) as a 16 
microarray platform. For Illumina BeadArray assay, cRNA was synthesized with an 17 
Illumina® RNA Amplification Kit (Ambion, Austin, TX) per the manufacturer’s 18 
 9
instructions. In brief, 500 ng of total RNA from PBMCs were reverse transcribed to 1 
synthesize first- and second-strand cDNA, purified with spin columns and then in vitro 2 
transcribed to synthesize biotin-labeled cRNA. A total of 750 ng biotin-labeled cRNA 3 
was hybridized to each Illumina Human Ref8 BeadChip arrays (Illumina) at 55 °C for 4 
18 h. The hybridized BeadChip was washed and labeled with streptavidin-Cy3 (GE 5 
Healthcare) and then scanned with the Illumina BeadStation 500 System (Illumina). The 6 
scanned image was imported into BeadStudio software (Illumina) for analysis. 7 
Twenty-two thousand transcripts representing 8 whole-genome samples can be analyzed 8 
on a single BeadChip. We included at least 1 technical replicates (i.e., the same cRNA 9 
samples) for each BeadChip. The correlation coefficient for identical RNAs was 0.993 10 
to 0.998 (r2) in the present study.  11 
 12 
Quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR)   13 
PBMCs from children of each group were purified by Ficoll-PaqueTM gradient (GE 14 
Healthcare). Total RNA was extracted from PBMCs with an RNeasy Kit (Qiagen). 15 
Quantitative real-time RT-PCR was performed with the TaqMan Universal Master Mix 16 
and Assay-on-Demand Gene Expression Kit (Applied Biosystems, Foster City, CA) per 17 
the manufacturer’s instructions. The endogenous control GAPDH was used to normalize 18 
 10
the sample with the ΔΔCT method for relative quantification with SDS software 2.2 1 
(Applied Biosystems).  2 
 3 
Molecular network and gene ontology (GO) analysis 4 
GO analysis was performed with the Database for Annotation, Visualization 5 
and Integrated Discovery (DAVID 2.0, http://david.abcc.ncifcrf.gov/) [12]. DAVID 2.0 6 
assigns genes of interests to GO: Biological Process categories of the Gene Ontology 7 
Consortium (www.geneontology.org) and identifies overrepresented categories for the 8 
genes of interest within the biologic process system. 9 
To investigate whether differentially expressed genes belong to specific 10 
pathways or networks, we used IPA version 6.0 software (IngenuityTM Systems, 11 
Mountain View, CA). This software is web-based and allows identification of biologic 12 
networks relevant to each researcher’s experiment. A data set containing the gene 13 
identifiers and the corresponding expression values was uploaded into the Ingenuity 14 
Pathways Knowledge Base. These uploaded genes (referred to as focus genes) were then 15 
used as the starting points for generating biologic networks, and the network was 16 
constructed to be enriched with the genes of interest. IPA also determines a statistical 17 
score for each network according to the fit of the network to the set of focus genes. The 18 
 11
score is the negative log of P and denotes the likelihood of the focus genes in the 1 
network being found together due to chance.  2 
  3 
Statistical Methods 4 
For microarray analysis, background-corrected values for each probe on the BeadChip 5 
array were extracted using BeadStudio version 1.5.1.3 (Illumina). Detection P values 6 
were computed from the background model characterized by the chance that the target 7 
sequence signal was distinguishable from the negative controls on the same chip. This is 8 
based on the average of negative control genes and is called the method of background 9 
normalization by Illumina. The extracted values were exported to the software 10 
GeneSpring version 7.3.1 (Silicon Genetics, Redwood, CA), and per chip and per gene 11 
normalization were performed. The statistical significance of the microarray data was 12 
calculated using the Welch t-test, and multiple tests were corrected by the Benjamini 13 
and Hochberg false discovery rate [13]. An analysis of covariance (ANCOVA) using the 14 
proportions of lymphocyte, basophil, and monocyte counts as the covariate and a 15 
random sampling procedure was performed using the R version 2.7.0 16 
(http://www.r-project.org/). The sample size calculation was calculated with the samr 17 
package for the R language (http://www-stat.stanford.edu/~tibs/SAM/) [14]. Statistical 18 
 12
significance of real-time RT-PCR was calculated with Mann-Whitney U test. 1 
Significance was defined as P < 0.05. 2 
 3 
 13
Results 1 
Our data processing strategy is outlined in Figure. We first identified transcripts that 2 
were expressed by at least 20 of the 34 samples on Human Ref8 BeadChip arrays with 3 
the detection P values < 0.01. Among the 12,073 expressed transcripts, those satisfying 4 
all of following criteria were selected as up/down-regulated transcripts in the microarray 5 
analysis : (1) more than 2-fold increase/decrease on average and (2) transcripts showing 6 
statistically significant differences between asthma exacerbation and stable status (q < 7 
0.05). The power of the study using sample sizes 12 vs 12 was approximately 0.6 with 8 
the following assumptions; mean difference of 2.5-fold for AE vs SA; total number of 9 
genes, 10,000; and hypothesized number of truly non-null genes, 200. The power was 10 
approximately 0.8 with a mean difference of 3.0-fold (supplementary Figure 1). 11 
Therefore, our sample size was sufficient for the detection of genes having moderate 12 
differences in expression, but it may not be enough for genes displaying small 13 
difference in expression.  14 
A total of 158 transcripts were up-regulated, and 31 transcripts were 15 
down-regulated 2-fold (in total, 189 transcripts); further, the change in the expression of 16 
153 (137/16 = up/down-regulated) transcripts was statistically significant (q < 0.05). 17 
Because asthma exacerbation is often associated with respiratory infection, we also 18 
 14
analyzed the genes that were differentially expressed during upper respiratory infection. 1 
Of the 153-asthma exacerbation-related genes, nearly half (62 genes) were differentially 2 
expressed with q values < 0.05. The genes that were up- and down-regulated in PBMCs 3 
during asthma exacerbation and upper respiratory infections are listed in Table 2 (q < 4 
0.001) and supplementary Table 1 (>2-fold changed transcripts).  5 
Because the statistical power of the NC vs IC comparison was approximately 6 
half of that obtained by comparing of the AE vs SA, the head-to-head comparison of the 7 
q values was not valid. In order to verify the results in Table 2 and supplementary Table 8 
1, we randomly selected 6 samples each from the AE and SA groups 10 times and 9 
performed the Welch’s t-test (supplementary Table 2). The results obtained were 10 
generally similar, and approximately two-third of 153 asthma exacerbation-related 11 
transcripts showed trends for significance (number of unadjusted P values < 0.05, 12 
average 100, range 92–106). Repetition of the procedure for 100 times also showed 13 
similar results (number of unadjusted P values < 0.05, average 99, range 88–111), 14 
suggesting that particular samples of the dataset are unlikely to influence the overall 15 
results. However, the results obtained using 6 AE vs. 6 SA samples were not as 16 
significant as those obtained using 12 AE vs. 11 SA samples because the P values were 17 
influenced by the number of samples in the test.  18 
 15
There was an inter-group variability in the monocyte cell composition in 1 
PBMC (P < 0.05, Table 1), and in order to incorporate the cell composition as a 2 
covariate, we performed ANCOVA analysis using 189 transcripts that were 2-fold 3 
upregulated or downregulated along with the cell composition data obtained from the 4 
microarray experiment (supplementary Table 1). The results obtained from the 5 
ANCOVA analysis did not differ considerably from those obtained without the 6 
incorporating cell composition data.  7 
 GO analysis revealed that the genes which were up- and down-regulated during 8 
asthma exacerbation could be categorized into those involved in defense responses and 9 
responses to external stimuli (q < 0.05). However, these associations disappeared after 10 
excluding the 62 infection-related genes (q > 0.05, Table 3).  11 
Pathway analysis was used to identify networks of genes that interact 12 
functionally with each other. The results of pathway analysis using 91 asthma 13 
exacerbation-related genes that are not associated with respiratory infections are shown 14 
in Table 4 and supplementary Figures 2–5. Four networks were identified for asthma 15 
exacerbation. The IPA software generates a large global molecular network based on 16 
hundreds of thousands of curated direct and indirect physical and functional interactions 17 
between orthologous mammalian genes from the published, peer-reviewed content in 18 
 16
the Ingenuity Knowledge Base. Several highly connected genes were identified in these 1 
networks, indicating that they are hub genes.  2 
We performed quantitative real-time RT-PCR to verify the results of microarray 3 
analysis. Several transcripts of the same genes were included in the microarray analysis, 4 
and some showed a discordant expression pattern (i.e. one transcript variant showed 5 
up/down regulation in the asthma exacerbation samples, but the others showed the 6 
opposite pattern of expression); therefore, we chose genes with a consistent pattern of 7 
expression or small genes with a single transcript in the microarray analysis. The results 8 
of quantitative real-time RT-PCR results of the selected genes confirmed that the 9 
expression of these genes was elevated during asthma exacerbation (P < 0.01, Table 5). 10 
The differences in the expressions of the CD200 and Retinol binding protein 7 (RBP7) 11 
genes between the IC and NC groups were not statistically significant (P > 0.05), while 12 
S100 calcium-binding protein A9 (S100A9) and growth arrest-specific 6 (GAS6) were 13 
highly up-regulated in the IC group (P < 0.01) relative to the expressions in the NC 14 
group.  15 
 17
Discussion 1 
In the present study, we performed microarray analysis to identify genes related to 2 
asthma exacerbation in children, and identified 153 up/down-regulated genes during 3 
asthma exacerbations.  4 
Up/down-regulated genes in patients who required hospitalization for asthma 5 
exacerbation were involved in defense responses and nearly half the asthma 6 
exacerbation-related genes were differentially expressed during upper respiratory 7 
infection, in spite of excluding children with fever and elevated CRP. These results 8 
suggest that most asthma exacerbations are related to infections, or that asthma 9 
exacerbation and respiratory infections share a common underlying mechanism.   10 
There are a number of limitations to the present study. First, we used PBMCs, 11 
which are a heterogeneous population of cells. It is possible that the differential 12 
expression of genes observed in this study merely reflects changes in the distributions of 13 
various cell populations. However, such changes do not occur without changes in 14 
intracellular signal transduction and gene expression [15]. ANCOVA analysis using cell 15 
composition data revealed that the results did not differ considerably from those 16 
obtained without incorporating the cell composition data. Also, we retrieved the 17 
expression data of the transcripts in T cells, B cells, natural killer cells, monocytes and 18 
 18
dendritic cells from the GNF SymAtlas database (http://wombat.gnf.org/SymAtlas/), 1 
and the expressions of these transcripts were not restricted to particular populations of 2 
cells (data not shown). These results suggest that the changes that take place in 3 
transcription during asthma exacerbations are less likely to be greatly influenced by the 4 
changes in particular populations of cells.    5 
Second, since the sample size of the NC vs IC groups was small, the power to 6 
detect the infection-related genes may be not sufficient. GO analysis (Table 3) showed 7 
that infection-related gene functions such as defense responses and response to external 8 
stimuli did not show any association after the 62 infection-related genes were removed, 9 
suggesting that we had excluded some of the infection-related genes during analysis. 10 
However, we cannot exclude the possibility that true infection-related genes were also 11 
included in the remaining 91 transcripts.   12 
Third, we did not test for the presence of viruses in the samples collected from 13 
the AE and IC groups. Asthma exacerbation is often associated with not only viral 14 
respiratory infection [16] but also other pathogens such as Mycoplasma pneumoniae and 15 
Chlamydophila pneumoniae [17]. In the present study, we used samples from patients 16 
with respiratory tract infections and identified the asthma-exacerbation-related genes 17 
that were not associated with respiratory infection, i.e. nearly half the total number of 18 
 19
asthma exacerbation-related genes.  1 
CD200 is type 1a transmenbrane protein expressed by thymocytes, activated T 2 
cells, B cells, dendritic cells, endothelial cells and neurons [18]. CD200/CD200R 3 
interactions transmit inhibitory signals to cells of the haematopoetic lineage, and these 4 
interactions are reported to play various roles in immune responses such as the 5 
induction of regulatory T cells [19] and tumor suppression [20]. A recent study revealed 6 
that the CD200 fusion protein significantly reduced the severity of experimental arthritis 7 
in mice and the expression of genes encoding proinflammatory cytokines such as tumor 8 
necrosis factor, IL-1B and IL-10 [21]. Our results showed that CD200 expression was 9 
significantly reduced during asthma exacerbation and that this reduction was not due to 10 
infection, suggesting that CD200 could be used for the treatment of patients with 11 
asthma exacerbation. RBP7 belongs to the fatty acid binding protein family and binds 12 
all-trans-, 13-cis-, and 9-cis-retinol with relatively high affinity [22]. RBP7 is expressed 13 
in various tissues, and it has been shown that human peroxisome proliferator-activated 14 
receptor alpha (PPARalpha) can regulate the hepatic RBP7 level in response to synthetic 15 
PPAR ligands [23]. PPARalpha and PPARgamma have been shown to exert potent 16 
anti-inflammatory effects that are primarily mediated through the modulation of 17 
pro-inflammatory gene expression and inflammatory cell functions [24], and these were 18 
 20
highly connected in the network analysis (Table 4). The role of RBP7 in immune 1 
reactions has not yet been examined, and a further study is needed to elucidate the role 2 
of RBP7 for immune responses.  3 
In conclusion, the present study identified the genes related to asthma 4 
exacerbation, and half of these genes were differentially regulated during respiratory 5 
infection. We identified the asthma-exacerbation related genes that were not associated 6 
with infection and some of these results were validated using RT-PCR. Although the 7 
regulation and function of these genes in asthma are mostly unknown, these gene 8 
signatures for asthma exacerbation provide further clarification of the molecular 9 
mechanisms that underlie asthma. 10 
 11 
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Figure legends  1 
Figure  Gene expression profiling strategy and general work flow. Human-Ref8 2 
Expression Bead CHIP (Illumina) were used to identify genes differentially expressed 3 
during asthma exacerbation. * AE/SA was calculated by dividing the gene expression 4 
levels in asthma exacerbation (AE) by those in the stable condition (SA). IC: infeced 5 
controls. NC: non-infected controls. 6 
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Table 1.  Characteristics of samples 1 
Table 1.  Characteristics of samples
AE* (n=12) SA* (n=11) IC* (n=6) NC* (n=5) P value** P value$
Mean (range) Mean (range) Mean (range) Mean (range) Total cell count
Propotion in
PBMC
Age (year) 7.5（3-14） 7.0（3-12） 3.8（3-6） 5.8（3-13） 0.877
No. of male/female 4/8 5/6 3/3 2/3
Classification of asthma severity  (moderate/severe) 7/5 6/5
Severity of asthma exacerbation  (moderate/severe) 2/10
Whole blood cell count  (/μl) 11,650 (7,800-14,700) 9,536  (6,500-16,000) 9,700 (4,300-13,200) 8,060 (4,900-9,500) 0.021
          Lymphocytes 2,449  (1,176-4,305) 3,893  (2,492-8,480) 2,208  (1,204-3,288) 3,770  (1,936-5,605) 0.006 0.084
          Eosinophils 614  (0-1,575) 765  (405-988) 100  (0-181) 119  (95-142) 0.407 -
          Monocytes 423  (0-775) 404  (198-658) 624  (387-792) 282  (279-285) 0.9 0.028
          Basophils 32  (0-82) 76  (0-376) 19  (0-43) 57  (20-95) 0.2 0.564
CRP (mg/dl) 0.3  (0.0-0.9) 0.0  (0.0-0.1) 0.8  (0.5-1.2) 0.0 0.059
Total serum IgE  (IU/ml) 1,225  (49-5,000) 1,341  (507-2,600) 0.237
Dermatophagoides farinae -specific IgE  (UA/ml) 74.8  (1.2-100) 96.5  (65.2-100) 0.242
 2 
*AE: Asthma exacerbation, SA: Stable asthma, IC: Infected control, NC: Non-infected 3 
control 4 
** P values were calculated by comparing cell counts between AE and SA groups 5 
$P values were calculated by comparing proportions in PBMC between AE and SA 6 
groups. Proportions of lymphocytes, monocytes and basophils were calculated with 7 
dividing them by the sum of lymphocytes, monocytes and basophils. 8 
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Table 2.  Asthma exacerbation related genes 1 
Fold 
Gene Name Description change* AE vs SA** IC vs NC** Accession$
Up-regulation
SVIL Supervillin 3.3 0.00041 0.442 NM_003174
CAST Calpastatin 3.2 0.00040 0.729 NM_001750
CREB5 cAMP responsive element binding protein 3.1 0.00069 0.001 NM_001011666
CSDE1 Cold shock domain containing E1 2.9 0.00019 0.746 NM_001007553
LATS2 LATS, large tumor suppressor, homolog 2 2.8 0.00040 0.330 NM_014572
DYSF Dysferlin, limb girdle muscular dystrophy 2.7 0.00082 0.011 NM_003494
ECGF1 Endothelial cell growth factor 1 2.7 0.00082 0.046 NM_001953
NFIX Nuclear factor I/X 2.7 0.00013 0.034 NM_002501
FLJ14107 Hypothetical protein FLJ14107 2.5 0.00023 0.796 NM_025026
BCL3 B-cell CLL/lymphoma 3 2.4 0.00034 0.050 NM_005178
RBP7 Retinol binding protein 7 2.4 0.00013 0.746 NM_052960
PRAM1 PML-RARA regulated adaptor molecule 1 2.4 0.00023 0.931 NM_032152
ALDH3B1 B1, transcript variant 2 2.3 0.00035 0.977 NM_001030010
S100A9 S100 calcium binding protein A9 2.3 0.00017 0.001 NM_002965
C1orf24 Chromosome 1 open reading frame 24 2.3 0.00065 0.320 NM_022083
PTPRE Protein tyrosine phosphatase, receptor 2.2 0.00036 0.070 NM_130435
LOC196463 Hypothetical protein LOC196463 2.2 0.00013 0.039 NM_173542
ECE1 Endothelin converting enzyme 1 2.2 0.00013 0.461 NM_001397
GRINA Glutamate receptor, ionotropic, N-methyl
D-asparate-associated protein 1
2.2 0.00013 0.115 NM_000837
IBRDC3 IBR domain containing 3 2.2 0.00013 0.184 NM_153341
GAS6 Growth arrest-specific 6 2.1 0.00065 0.003 NM_000820
UBTD1 Ubiquitin domain containing 1 2.1 0.00034 0.495 NM_024954
PHLDA1 Pleckstrin homology-like domain, family
A, member 1
2.1 0.00013 0.076 NM_007350
TAPBP TAP binding protein 2.1 0.00023 0.273 NM_172208
EPB49 Erythrocyte membrane protein band 4.9 2.1 0.00065 0.148 NM_001978
DKFZp761E198DKFZp761E198 protein 2.0 0.00041 0.004 NM_138368
CSF3R Colony stimulating factor 3 receptor 2.0 0.00019 0.208 NM_172313
IGF2BP2 Insulin-like growth factor 2 mRNA binding
protein 2
2.0 0.00013 0.934 NM_006548
C14orf58 Chromosome 14 open reading frame 58 2.0 0.00075 0.009 NM_017791
LIMK2 LIM domain kinase 2 2.0 0.00065 0.977 NM_001031801
Down-regulation
TIPRL TIP41, TOR signalling pathway regulator- 0.5 0.00050 0.796 NM_152902
CD200 CD200 antigen 0.5 0.00036 0.746 NM_001004196
FLJ21742 Hypothetical protein FLJ21742 0.5 0.00013 0.653 NM_032207
FBLN5 Fibulin 5 0.4 0.00065 0.094 NM_006329
q value
 2 
* The fold change was determined by calculating the ratio of global normalized signals from the 3 
PBMCs of AE group to those from the PBMCs of SA group. 4 
**AE: Asthma exacerbation, SA: Stable asthma, IC: Infected control, NC: Non-infected control 5 
$ GenBank accession numbers. 6 
Among the 153 asthma exacerbation-related genes, 34 genes with q < 0.001 are listed in this table. 7 
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Table 3. GO analysis for asthma exacerbation-related genes
All genes (n=153) Infection unrelated genes (n=91) 
P value (q value)* P value (q  value)*
defense response 5.1 x 10-10 (2.7 x 10-6） N/A$
response to wounding 8.2 x 10-10 (2.0 x 10-6） 0.014　(1.0）
inflammatory response 1.1x 10-8 (2.0 x 10-5） 0.16　(1.0）
response to external stimulus 2.1 x 10-8 (2.7 x 10-5） 0.027　(1.0）
response to stress 7.8 x 10-6 (5.9 x 10-3） 0.12　(1.0）
Gene function
 1 
*Exact probability of randomly sampling a given number of genes (up/down-regulated gene during 2 
asthma exacerbation) and observing a specific number that belongs to the gene functions. P values 3 
were corrected by the Benjamini and Hochberg false discovery rate, and expressed as q value. 4 
$P and q values were not available because the gene function was not significant with regard to 5 
genes that were not related to the infection. 6 
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Table 4.  Gene networks identified by pathway analysis
Network
ID Genes in network Score
* Detected
genes**
Top functions Hub genes§
1
 Akt, BAIAP2, CAST, CD200, CSDE1,
CSF3R, CTDSP1, ERK, FBLN5,
HDAC9, Histone h3, Jnk, Mapk, MBP,
Nfat, NFAT5, NFkB, NFKBIZ, PAK2,
PDGF BB, PHLDA1, Pkc(s), PPHLN1,
PPM1B, PRAM-1, PTGDR, PTPRC,
PTPRE, Rac, RNASE2, RNF19B, S100P,
TFPI, TGM2, TNFRSF10D
56 25
Cellular Assembly and
Organization, Nervous
System Development and
Function, Cell-To-Cell
Signaling and Interaction
Histone h3, Jnk,
Mapk, Nfat5,
NFkB,
2
 APOA1, ARHGAP11A, C19ORF44,
CLPB, DDX3Y, DHX8, DSC2, EWSR1,
F12, FAM129A, FYTTD1, GOLIM4,
HNF4A, HOXA9, HP, KRR1, L-
triiodothyronine, LILRA3, LIMS1,
MINA, MRPS18B, MYC, NBPF3,
NBR1, PARVB, PF4V1, PTGDS,
RMND5B, RPL41, SF1, SHBG,
SLC25A19, TCIRG1, TCN1, ZNHIT3
31 16 Cancer, Cell Morphology,Hematological Disease EWSR1, HNF4A
3
 AGT, AKAP9, Ca2+, CACNG5, CCR9,
DLG4, EPB49, FCN2, GHRL, GPD2,
IGF2BP2, LATS2, MAP2K4, MAP3K14,
MAPK3, MKK3/4/6, NLRP12, NMDA
Receptor, NRCAM, PPAR&gamma;
ligand-PPAR&gamma;-Retinoic acid-
RAR&alpha;, PPARG, PVALB, retinoic
acid, RNASE, S100A12, SLC8A3,
SPIN1, SSH1, SSH2, SSH3, TAOK1,
VNN1, YWHAA, YWHAB, YWHAE
29 15
Gene Expression, Cancer,
Immune and Lymphatic
System Development and
Function
AGT, MAP2K4,
PPARG, YWHAB
4
 ARF4, ASPM, ATRX, CDKN1A,
COL16A1, dihydrotestosterone, ECE1,
GNB4, HIST1H4C, KLF7, LIMK2,
LOC100129193, LYVE1, MBOAT5,
MSMB, NFKBIA, NKIRAS2, NNMT,
PDZK1IP1, PLXNC1, PPARA, RBP7,
S100A11, SERPINB10, SLC1A4, SVIL,
TAPBP, Tgf beta receptor, TGFB1,
TGFBR2, TGFBRAP1, TNF, TPM4,
Type I / Type II receptor, YTHDC1
26 14
Cancer, Cellular Function
and Maintenance,
Reproductive System
Disease
PPARA, TGFB1,
TGFBR2,  TNF
 1 
* Score is based on Fisher exact test and the score > 3 corresponds to P < 0.001. 2 
** Pathway analysis was constructed using the 91 asthma exacerbation-related genes that were not 3 
associated with the infection. Among the network genes, the genes detected in our microarray 4 
analysis are underlined. 5 
§ Genes that were highly connected (>5 connections) in the network. 6 
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Table 5.  Result of quantitative RT-PCR 1 
Gene Name Fold change* P  values**
S100A9 2.4 <0.0001
GAS6 1.8 0.0003
RBP7 1.5 0.0003
CD200 0.5 0.0003  2 
* The fold change was determined by dividing mean relative quantification values of AE group by 3 
those of SA group. 4 
**P values were calculated with Mann-Whitney U test 5 

